12/02/2026
Cannabinoids can trigger cancer cell death and block tumor growth.
Emerging research into the endocannabinoid system suggests that compounds like THC and CBD may possess significant anti-tumor properties.
In laboratory and animal models, these cannabinoids interact with specific receptors to trigger apoptosis—a process where cancer cells are essentially programmed to self-destruct—while leaving healthy tissue unharmed. Beyond cell death, these compounds have demonstrated the ability to inhibit cell division and block angiogenesis, the process by which tumors grow new blood vessels to sustain their spread. These findings offer a potential roadmap for targeting aggressive cancers of the brain, breast, and lungs.
Despite these promising biological signals, the medical community maintains that cannabis is not an FDA-approved standalone treatment for cancer. Current clinical evidence is largely limited to small trials and palliative use, where cannabinoids effectively manage chemotherapy-induced nausea, chronic pain, and appetite loss. While some studies suggest cannabinoids may work synergistically with chemotherapy to overcome drug resistance, the high degree of tumor heterogeneity means effects vary significantly between patients. Consequently, oncology experts urge patients to coordinate any cannabis use with their medical team to prevent potential drug interactions and ensure it does not interfere with life-saving conventional therapies.
source: National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press.
